Post-Transplant Cyclophosphamide with Extended Abatacept for GVHD Prophylaxis Following Haploidentical Transplantation for Non-Malignant Disorders

Key Points

• GVHD prophylaxis improves following haploidentical transplantation, enhancing patient recovery and safety.
• Key metrics show a reduced incidence of graft-versus-host disease post-transplant using cyclophosphamide and abatacept.
• Treatment combines post-transplant cyclophosphamide with extended use of abatacept for stronger anti-GVHD effects.
• This analysis highlights the importance of effective prophylaxis strategies to improve organ acceptance and patient health.